Cidofovir dihydrate

Category	Cytomegalovirus (CMV)
CAS	149394-66-1
Description	Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription. It is an acyclic nucleoside phosphonate, and is therefore independent of phosphorylation by viral enzymes, unlike acyclovir. Cidofovir was discovered at the Institute of Organic Chemistry and Biochemistry, Prague, and developed by Gilead Sciences and is marketed with the brand name Vistide by Gilead in the USA, and by Pfizer elsewhere. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions.

Quotation Now

Synonyms	HPMPC dihydrate; Vistide dihydrate; (S)-HPMPC dihydrate
IUPAC Name	[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid;dihydrate
Molecular Weight	315.22
Molecular Formula	C8H18N3O8P
Canonical SMILES	C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O.O.O
InChI	InChI=1S/C8H14N3O6P.2H2O/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16;;/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16);2*1H2/t6-;;/m0./s1
InChIKey	FPKARFMSZDBYQF-ILKKLZGPSA-N
Boiling Point	609.5°C at 760 mmHg
Melting Point	260°C (dec)
Flash Point	322.4±34.3 °C
Purity	>98%
Density	1.76 g/cm3
Solubility	Soluble in DMSO
Appearance	White Powder
Application	Antiviral Agents
Storage	Store at RT
Complexity	417
Exact Mass	315.08315154
Index Of Refraction	1.656
PSA	157.71000
Target	CMV; DNA/RNA Synthesis; Orthopoxvirus; Apoptosis; Endogenous Metabolite
Vapor Pressure	0.0±4.0 mmHg at 25°C